Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information-Reference-Cited by-同舟云学术

Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information

Published:2023-05-01 Issue: Volume: Page:
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Boujonnier François,Lemaitre Florian,Scailteux Lucie-Marie^ORCID

Funder

Agence Nationale de Sécurité du Médicament et des Produits de Santé

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10557-023-07453-0.pdf

Reference71 articles.

1. Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479–99.

2. European Medicines Agency. Zytiga. EPAR - Public assessment report. 2011. [Internet]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/zytiga-epar-public-assessment-report_en.pdf

3. Cattrini C, Caffo O, De Giorgi U, et al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers. 2022;14:1792.

4. European Medicines Agency. Erleada. EPAR - Public assessment report (Procedure No. EMEA/H/C/004452/0000). [Internet]. 2019. Available from: https://www.ema.europa.eu/en/documents/assessment-report/erleada-epar-public-assessment-report_en.pdf

5. European Medicines Agency. Nubeqa. EPAR - Public assessment report. [Internet]. 2020 Apr. Available from: https://www.ema.europa.eu/en/documents/assessment-report/nubeqa-epar-public-assessment-report_en.pdf

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact;Expert Opinion on Drug Metabolism & Toxicology;2024-05-22

2. Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy;Drug Safety;2024-04-12